Online inquiry

IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12826MR)

This product GTTS-WQ12826MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MASP2 gene. The antibody can be applied in Atypical hemolytic uremic syndrome (aHUS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_006610.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10747
UniProt ID O00187
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12826MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6267MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ15374MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ424MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ6374MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ6645MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ12370MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ15386MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ9587MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW